News | News By Subject | News by Disease News By Date | Search News

Benign prostatic hypertrophy News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Sophiris Bio Inc. (SPHS) Tanks As Phase 3 Data Indicates Drug May Not Be Effective     12/16/2014
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Eli Lilly and Company (LLY) Gets Positive CHMP Opinion for Cialis 5 Mg to Treat BPH     9/21/2012
Protox Therapeutics Inc. (PRX.V) Signs $75 Million License Agreement with Kissei Pharmaceutical Co., Ltd. for Commercialization of PRX302 in Japan for BPH and Prostate Disease     4/30/2010
Recordati S.p.A Buys Jaba Farmacêutica And Other Pharmaceutical Businesses In Portugal For Approximately EUR 45 Million     7/28/2006
Threshold Pharmaceuticals, Inc. (THLD)'s Phase 2 And Phase 3 Clinical Trials Of TH-070 In Benign Prostatic Hyperplasia (BPH) Do Not Meet Primary Endpoint     7/17/2006
Teva Pharmaceutical Industries Limited (TEVA) Receives First FDA Approval For Generic Proscar(R) Tablets     6/19/2006
Threshold Pharmaceuticals, Inc. (THLD) Announces Changes To TH-070 Clinical Development Program; FDA Partially Suspends Drug Trial     5/12/2006
Nymox Pharmaceutical (NYMX) Reports Latest Interim Review Of Safety Data For Benign Prostatic Hyperplasia Drug     4/21/2006
AEterna Zentaris (AEZS) Regains Exclusive Worldwide (ex-Japan) Rights For Cetrorelix In Benign Prostate Hyperplasia     1/30/2006
Nymox Pharmaceutical (NYMX) Reports Positive New Data For Benign Prostatic Hyperplasia (BPH) Drug     6/8/2005
Astellas Pharma Inc., Boehringer Ingelheim Pharmaceuticals, Inc. Jointly Sue Ranbaxy Laboratories's Flomax Generic For Patent Infringement In US     5/17/2005
AEterna Zentaris Reports Statistically Significant Positive Phase II Data On Cetrorelix In Benign Prostatic Hyperplasia     10/7/2004

News from Around the Web
Surgery Outperforms Drug Therapy in Treatment of Benign Prostatic Hyperplasia, Mayo Clinic Study     6/1/2010
Eli Lilly and Company (LLY) Impotence Drug Treats Prostate Enlargement, University of Texas Southwestern Medical Center and Northwestern University Study     8/19/2008
Pain Meds May Worsen Symptoms of Enlarged Prostate     9/24/2007
Can Erectile Dysfunction Drugs Improve Lower Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia     5/23/2007
Common Pain Relievers Reduce Prostate Swelling     10/18/2006
Herb Not Effective For Enlarged Prostate     2/9/2006
Botox May Ease Enlarged Prostate Symptoms     5/12/2004
New Drug To Treat Enlarged Prostate Developed At University College London     12/1/2003
Prostate Symptoms May Worsen Rapidly For Black Men     11/19/2003

Press Releases
Nymox (NYMX) Announces Validation By The European Member States Of European Marketing Authorization Application For Fexapotide Triflutate For Benign Prostatic Hyperplasia     9/15/2017
Merit Medical (MMSI)’s Embosphere Microspheres Receive FDA 513(F)(2) (De Novo) Classification For Prostatic Artery Embolization Indication     6/22/2017
Nymox (NYMX) Reports Additional Positive Results From Completed Fexapotide BPH Phase III Studies Showing Significant Early Response And First-Line Efficacy     11/29/2016
Nymox (NYMX)'s New Phase III Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show     8/29/2016
Nymox Pharmaceutical (NYMX) Announces Prostate Drug Progress     8/11/2016
Boston Scientific (BSX) Nabs UK NICE Support for Greenlight Laser Therapy     6/17/2016
NeoTract, Inc. Announces Data Showing Excellent Durability Of Results For Urolift System At Four Years     5/9/2016
Teva (TEVA) Announces Exclusive Launch Of Generic Avodart Capsules In The United States     10/12/2015
Nymox Pharmaceutical (NYMX) July 27 Webcast Of New BPH Clinical Trial Results Posted Today Online     7/29/2015
CeloNova BioSciences Receives Expanded Indication For Benign Prostatic Hyperplasia (BPH)     1/14/2015
Sophiris Bio Inc. (SPHS) Reports Administrative Interim Analysis For The "PLUS-1" Phase 3 Trial Of PRX302 For Benign Prostatic Hyperplasia     12/15/2014
Sophiris Bio Inc. (SPHS) Reports Completion Of Enrollment In The "PLUS-1" Phase 3 Trial Of PRX302 For Benign Prostatic Hyperplasia     9/2/2014
Nymox Pharmaceutical (NYMX) Announces Completion Of Enrollment For Second BPH Re-Injection Study     7/15/2014
Nymox Pharmaceutical (NYMX) Reports Positive Update On Nerve Sparing And Sexual Function Preservation In Men Treated With NX-1207     6/17/2014
Nymox Pharmaceutical (NYMX) Reports Positive New Safety Study Data For Phase 3 BPH Drug     6/12/2014